Table 3: Frequency distributions and MCA quantifications* of the primary and secondary outcomes.

T0 (baseline)T1 (after 14 days)T2 (after 28 days)
012301230123

Functional dyspepsia
(primary outcome)
S10262549152120
P2627802917132
Q01.232.523.2800.981.862.78

Epigastric fullnessS2251622302195401654
P12141322142117917221210
Q01.451.872.5201.612.252.6101.692.132.46

BloatingS3071117371412246892
P1317191215241841920193
Q01.612.082.3701.642.272.4701.742.132.40

Early satietyS522655752161220
P361348381751411451
Q02.242.142.1402.192.572.7502.422.752.91

NauseaS21792832219351671
P221218923251032718115
Q01.792.172.1801.672.392.5901.862.192.37

VomitingS611216230063200
P489135362052720
Q02.333.583.5902.526.2702.526.28

Epigastric painS36816546126153561
P3339163210118348109
Q00.781.512.6201.252.142.9601.471.982.93

S = supplementation frequencies, P = placebo frequencies, and Q = normalized modalities quantify by MCA algorithm (in bold).
*MCA quantifications define scaled severity scores for each outcome.